1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Asia Pacific Antacids Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Asia Pacific Antacids Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Asia Pacific Antacids Market Regional Analysis
6.2 Asia Pacific Antacids Market Revenue 2017-2027 (US$ Million)
6.3 Asia Pacific Antacids Market Forecast Analysis
7. Asia Pacific Antacids Market Analysis – by Dosage Form
7.1 Tablet
- 7.1.1 Overview
- 7.1.2 Tablet: Asia Pacific Antacids Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.2 Liquid
- 7.2.1 Overview
- 7.2.2 Liquid: Asia Pacific Antacids Market – Revenue and Forecast, 2017-2027 (US$ Million)
8. Asia Pacific Antacids Market Analysis – by Drug Class
8.1 Proton Pump Inhibitors
- 8.1.1 Overview
- 8.1.2 Proton Pump Inhibitors: Asia Pacific Antacids Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.2 H2 Antagonist
- 8.2.1 Overview
- 8.2.2 H2 Antagonist: Asia Pacific Antacids Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.3 Acid Neutralizers
- 8.3.1 Overview
- 8.3.2 Acid Neutralizers: Asia Pacific Antacids Market – Revenue and Forecast, 2017-2027 (US$ Million)
9. Asia Pacific Antacids Market Analysis – by Distribution Channel
9.1 Hospital Pharmacy
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacy: Asia Pacific Antacids Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.2 Retail Pharmacy
- 9.2.1 Overview
- 9.2.2 Retail Pharmacy: Asia Pacific Antacids Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.3 Online Pharmacy
- 9.3.1 Overview
- 9.3.2 Online Pharmacy : Asia Pacific Antacids Market – Revenue and Forecast, 2017-2027 (US$ Million)
10. Asia Pacific Antacids Market – Asia-Pacific Analysis
10.1 Overview
10.2 Asia-Pacific
- 10.2.1 Asia Pacific Antacids Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 10.2.1.1 Asia Pacific Antacids Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 China:
Asia Pacific Antacids Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.1.1 China: Asia Pacific Antacids Market Breakdown, by Dosage Form
- 10.2.1.1.2 China: Asia Pacific Antacids Market Breakdown, by Drug Class
- 10.2.1.1.3 China: Asia Pacific Antacids Market Breakdown, by Distribution Channel
- 10.2.1.2 India:
Asia Pacific Antacids Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.2.1 India: Asia Pacific Antacids Market Breakdown, by Dosage Form
- 10.2.1.2.2 India: Asia Pacific Antacids Market Breakdown, by Drug Class
- 10.2.1.2.3 India: Asia Pacific Antacids Market Breakdown, by Distribution Channel
- 10.2.1.3 Japan:
Asia Pacific Antacids Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.3.1 Japan: Asia Pacific Antacids Market Breakdown, by Dosage Form
- 10.2.1.3.2 Japan: Asia Pacific Antacids Market Breakdown, by Drug Class
- 10.2.1.3.3 Japan: Asia Pacific Antacids Market Breakdown, by Distribution Channel
- 10.2.1.4 Australia:
Asia Pacific Antacids Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.4.1 Australia: Asia Pacific Antacids Market Breakdown, by Dosage Form
- 10.2.1.4.2 Australia: Asia Pacific Antacids Market Breakdown, by Drug Class
- 10.2.1.4.3 Australia: Asia Pacific Antacids Market Breakdown, by Distribution Channel
- 10.2.1.5 Rest of Asia-Pacific :
Asia Pacific Antacids Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.5.1 Rest of Asia-Pacific : Asia Pacific Antacids Market Breakdown, by Dosage Form
- 10.2.1.5.2 Rest of Asia-Pacific : Asia Pacific Antacids Market Breakdown, by Drug Class
- 10.2.1.5.3 Rest of Asia-Pacific : Asia Pacific Antacids Market Breakdown, by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Bayer AG
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 GlaxoSmithKline plc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Takeda Pharmaceutical Company Limited
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Sun Pharmaceutical Industries Ltd
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Sanofi
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Boehringer Ingelheim International GmbH
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Dr. Reddy's Laboratories
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Pfizer Inc
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Reckitt Benckiser Group Plc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Procter & Gamble
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations